Landmark Anvisa approval of Xcopri targets refractory epilepsy, boosting treatment options in 2025
The Brazilian Health Regulatory Agency (Anvisa) has officially approved a significant new medication, Xcopri (cenobamate), developed by Momenta Farmacêutica, for the treatment of focal onset seizures in adults suffering from drug-resistant epilepsy. This decision marks a pivotal moment for a substantial patient population, offering a much-needed therapeutic alternative where previous treatments have fallen short. The approval, anticipated to streamline access in 2025, addresses a critical gap in neurological care.
Drug-resistant epilepsy is a debilitating condition where individuals continue to experience seizures despite having tried at least two different anti-epileptic medications, impacting roughly 30% of all epilepsy patients. The constant threat of unpredictable seizures severely diminishes quality of life and often leads to significant social and professional challenges.
Cenobamate functions by targeting and reducing the abnormal electrical activity within the brain, which is the underlying cause of epileptic episodes. This mechanism offers a novel approach to stabilizing neural function and decreasing the frequency of these disruptive events.
A New Frontier in Epilepsy Treatment
Anvisa’s endorsement of cenobamate provides a new strategic tool for neurologists managing patients with complex forms of epilepsy. This drug is specifically tailored for individuals whose focal onset seizures have proven recalcitrant to standard pharmacological interventions, representing a significant hurdle in their long-term management.
The core efficacy of cenobamate lies in its ability to modulate voltage-gated sodium currents and enhance inhibitory gamma-aminobutyric acid (GABA) receptor activity. This dual action helps to calm overactive neuronal networks, thereby decreasing the likelihood of seizure propagation and occurrence.
Clinical trials underpinning the approval showcased compelling results. Data revealed that four out of ten patients receiving a 100-milligram daily dose experienced a reduction of at least 50% in seizure frequency. Furthermore, 64% of those on a higher 400-milligram daily regimen achieved the same level of improvement, starkly contrasting with the 26% improvement observed in the placebo group.
The Challenge of Refractory Epilepsy
Refractory epilepsy, often termed drug-resistant epilepsy, imposes a heavy burden on individuals and healthcare systems alike. Affecting millions worldwide, this form of the disorder is characterized by its persistence, defying conventional treatment protocols and necessitating innovative solutions.
For these patients, the continuous threat of seizures profoundly impacts daily routines, limiting independence and contributing to higher rates of anxiety, depression, and social isolation. The availability of new, effective medications is therefore paramount in improving their prognosis and overall well-being.
Path to Patient Access
The journey from Anvisa approval to widespread patient access is a multi-step process. Following this pivotal regulatory decision, Xcopri’s commercialization in Brazil awaits the official definition of its maximum sales price, a critical determination made by the Câmara de Regulação do Mercado de Medicamentos (CMED).
Potential Public Health Inclusion
For broader accessibility, particularly within the public health sector, Xcopri’s incorporation into the Unified Health System (SUS) is another significant hurdle. This process requires a comprehensive evaluation by the Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (Conitec), which assesses the drug’s clinical effectiveness, cost-effectiveness, and overall impact on public health.
A positive recommendation from Conitec would then pave the way for a final decision by the Ministry of Health, potentially allowing millions of Brazilians to access cenobamate through the public healthcare network. This inclusion would be transformative for patients facing financial barriers to treatment.
Understanding Epilepsy
Epilepsy is defined as a temporary and reversible disturbance in brain function, not caused by transient factors such as fever, substance use, or metabolic imbalances. It manifests as recurrent, unprovoked seizures, which are sudden, uncontrolled electrical discharges.
During a seizure, a specific area of the brain emits incorrect signals for a brief period, ranging from a few seconds to several minutes. These electrical disturbances can remain localized, resulting in what is known as a partial or focal seizure, or they can spread across both cerebral hemispheres, leading to a generalized seizure.
Diagnosis typically relies on a thorough clinical assessment, involving a general physical examination with particular attention to neurological and psychiatric aspects. A detailed medical history, often supplemented by observations from a witness who can accurately describe the seizures, is crucial for an accurate diagnosis.
Important details for healthcare providers include the occurrence of an “aura”—a sensation preceding a seizure where consciousness is not lost—along with any identifiable precipitating factors, the age at which seizures began, their frequency, and the intervals between episodes. This comprehensive information aids in tailoring effective management strategies.
Global Awareness and Local Impact
This timely approval coincides with “March Purple,” an international observance dedicated to raising awareness about epilepsy, culminating in World Epilepsy Awareness Day on March 26. This initiative strives to educate the public, diminish social stigma, and foster greater empathy and understanding towards those affected by the condition.
Globally, the World Health Organization (WHO) estimates that approximately 65 million individuals live with epilepsy, highlighting its widespread impact. In Brazil alone, over 2 million people are affected, many of whom contend not only with the complexities of treatment but also with pervasive prejudice and misinformation.
According to Juliana Passos, a distinguished neurologist and board member of the Brazilian League Against Epilepsy (LBE), this new medication signifies a profound leap forward, especially for patients battling epilepsy that is difficult to control. “This medication is indicated for the treatment of patients with drug-resistant epilepsy, and its results have been significantly superior to those achieved by other available anti-seizure medications. Offering a considerably greater chance of seizure control for these patients is an urgent necessity,” Passos affirms.
Future Outlook: AI in Diagnosis
As medical science advances, the landscape of epilepsy diagnosis and treatment continues to evolve, with emerging technologies like artificial intelligence playing an increasingly significant role. AI-powered diagnostic tools are now capable of detecting subtle cerebral abnormalities that might be invisible to the human eye in traditional imaging, potentially leading to earlier and more precise diagnoses. This integration of cutting-edge technology, combined with pharmacological breakthroughs such as Xcopri, paints a hopeful picture for patients, promising a future with improved management strategies, personalized treatment plans, and ultimately, a better quality of life for those living with epilepsy.






